Tablas de Dosis Calculadora Mezclas & Stacks Aprender Blog Péptidos Aprobaciones
Abrir Calculadora
Tablas de Dosis  ›  ACTH 1-39
Hormonal

ACTH 1-39 Guía & Tabla de Dosis

Full-length adrenocorticotropic hormone (39 amino acids) that stimulates adrenal cortisol release; the basis of approved corticotropin (Acthar) therapy.

También conocido comoCorticotropin, full-length ACTH
CAS9002-60-2
Víasubcutaneous
ACTH 1-39 — Tabla de dosis
Cada fila citada
ObjetivoDosisFrecuenciaDuraciónEvidenciaFuente
Los datos de dosis citados de este compuesto se están compilando.
Solo para uso de investigación y educativo. No es consejo médico.
Cómo Reconstituir ACTH 1-39
U-100

Enfoque común: reconstituir un vial de ejemplo de 5 mg de ACTH 1-39 con agua bacteriostática. La tabla muestra la concentración en tres volúmenes de agua comunes — usa la calculadora de esta página para tu dosis objetivo específica.

Agua BACConcentraciónVolumen / dosisUnidades (U-100)
1 mL5 mg/mL——
2 mL2.5 mg/mL——
3 mL1.67 mg/mL——

Las unidades mostradas son para una jeringa de insulina U-100 (1 mL = 100 unidades). Verifica siempre tus propios cálculos antes de cargar.

Tamaños de Vial de ACTH 1-39

Reconstitución resuelta para cada tamaño común de vial:

5 mgprotocolo del vial

What is ACTH 1-39?

ACTH 1-39 — short for adrenocorticotropic hormone, full length — is a 39-amino-acid peptide that your pituitary gland naturally makes and releases into the bloodstream. Think of it as the body's own "alarm messenger": when the brain senses stress or low cortisol, it fires off a signal that tells the pituitary to release ACTH 1-39, which then races to the adrenal glands (those little caps sitting on top of your kidneys) and tells them to produce cortisol.[6]

ACTH 1-39 is also called corticotropin. It is the active ingredient behind the long-approved drug Acthar (repository corticotropin injection), which has been used clinically for decades.[5] In the research world, scientists study ACTH 1-39 as a research compound to better understand how the hormone works — and whether it has effects beyond simply boosting cortisol.

Research use only. The information on this page is for educational and scientific reference purposes. ACTH 1-39 is not approved for self-administration, and nothing here is medical advice.

How ACTH 1-39 Works

Here is a simple way to picture it. Imagine your stress-response system as a chain of falling dominoes. The first domino is the brain's hypothalamus, which releases a chemical called corticotropin-releasing hormone (CRH).[1] That knocks over the second domino — the pituitary gland — which releases ACTH 1-39. ACTH 1-39 then travels through the blood to hit the third domino: the adrenal glands, which pump out cortisol.[6]

ACTH 1-39 does this by latching onto specific docking sites called corticotropin receptors (also known as melanocortin receptors) on adrenal cells.[2] When ACTH binds, it triggers a chain of chemical reactions inside the cell that results in cortisol being made and released.

But here is what makes ACTH 1-39 particularly interesting to researchers: melanocortin receptors are not only found on adrenal cells. They also appear on cells in the brain, including neurons and glial cells.[4] That means ACTH 1-39 may have effects on the nervous system that are completely separate from its role in cortisol production — a discovery that has opened up new lines of research.

What the Research Shows

Much of the recent scientific interest in ACTH 1-39 centers on the brain. Two studies from Wayne State University explored what happens when ACTH 1-39 is applied directly to nervous system cells in the laboratory.

  • Protecting neurons: In one set of experiments, rat forebrain neurons in culture were exposed to a range of damaging agents — things that trigger cell death through apoptosis (programmed cell death), excitotoxicity (over-stimulation), and inflammation. ACTH 1-39 protected the neurons from death caused by glutamate, NMDA, AMPA, kainate, quinolinic acid, and reactive oxygen species. It also offered modest protection against rapidly released nitric oxide.[4]
  • Protecting the myelin-making cells: A follow-up study looked at oligodendrocytes — the brain cells responsible for producing myelin, the protective coating around nerve fibers that is damaged in conditions like multiple sclerosis. Researchers found that ACTH 1-39 helped protect these cells from several toxic threats. Interestingly, part of this protection worked indirectly: ACTH 1-39 stimulated nearby support cells called astroglia to release their own protective signals, which then shielded the oligodendrocytes.[3]

On the pharmacology side, a clinical Phase 1 study compared repository corticotropin injection (Acthar Gel, which contains porcine ACTH 1-39 analogs) with a shorter synthetic version called ACTH 1-24 and with methylprednisolone in healthy volunteers. Despite higher blood levels of the ACTH 1-39 marker compound, the full-length version produced significantly lower cortisol output than ACTH 1-24 — about 5-fold lower free cortisol exposure. This finding suggests the two ACTH forms are not interchangeable, and that length and formulation matter in ways researchers are still working to understand.[5]

What ACTH 1-39 Is Being Studied For

Based on the research available, ACTH 1-39 is currently being investigated in the following areas:

  • Neuroprotection — shielding brain cells from damage caused by excitotoxicity and inflammation[4]
  • Myelin and oligodendrocyte biology — understanding how the hormone protects myelin-producing cells, relevant to demyelinating diseases[3]
  • HPA axis physiology — mapping how the hypothalamus-pituitary-adrenal stress system communicates[1][6]
  • Receptor pharmacology — studying how melanocortin receptors respond to full-length ACTH versus shorter fragments[2]
  • Pharmacokinetic comparisons — understanding differences between ACTH 1-39, ACTH 1-24, and steroid drugs[5]

How ACTH 1-39 Is Dosed in Research

Because ACTH 1-39 is a research compound studied under controlled laboratory or clinical conditions, dosing varies widely depending on the model, the endpoint being studied, and the formulation used. The Phase 1 clinical study referenced here used subcutaneous administration in a structured protocol.[5] For a full breakdown of the doses and units used across different research contexts, please refer to the dosage chart on this page and use the calculator to work through unit conversions. No dosing information on this page should be interpreted as guidance for human self-administration.

Mixing and Storing ACTH 1-39

In a research setting, lyophilized (freeze-dried) ACTH 1-39 powder is typically reconstituted by adding bacteriostatic water or sterile saline slowly to the vial — do not shake; gently swirl until fully dissolved. Use only the solvent specified by your supplier's certificate of analysis. Once reconstituted, the solution should be stored at 2–8 °C (standard refrigerator temperature) and used within the timeframe specified by the manufacturer, typically within a few days to a week for best stability. Peptides are sensitive to repeated temperature swings, so avoid leaving vials at room temperature longer than necessary. Lyophilized (dry, unopened) stock should be stored frozen at −20 °C or colder, away from light and moisture. Always label vials with the date of reconstitution.

Sources

  1. Corticotropin-releasing factor. — Endocrine reviews, 1982. PMID 6282576.
  2. Corticotropin receptors. — Annals of the New York Academy of Sciences, 1987. PMID 2831782.
  3. The melanocortin ACTH 1-39 promotes protection of oligodendrocytes by astroglia. — Journal of the neurological sciences, 2016. PMID 26944112.
  4. Melanocortin receptor agonist ACTH 1-39 protects rat forebrain neurons from apoptotic, excitotoxic and inflammation-related damage. — Experimental neurology, 2015. PMID 26300474.
  5. Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH(1-24) Depot and Methylprednisolone in Healthy Subjects. — Clinical pharmacology in drug development, 2022. PMID 34528408.
  6. Corticotropin-releasing hormone. — The New England journal of medicine, 1988. PMID 3292914.
Materiales Necesarios

Un kit típico de reconstitución e inyección incluye:

  • Vial(es) de péptido liofilizado — suficiente para todo el protocolo
  • Agua bacteriostática para la reconstitución
  • Jeringas de insulina U-100 (una por inyección)
  • Toallitas de alcohol
  • Un contenedor de objetos punzantes para desecho seguro
Almacenamiento, Manejo e Inyección

Almacenamiento y manejo

El péptido liofilizado se suele mantener refrigerado y protegido de la luz; una vez reconstituido con agua bacteriostática, normalmente se refrigera a 2–8 °C y se usa en pocas semanas. Sigue la técnica aséptica para evitar la contaminación, según la guía de seguridad en inyecciones de CDC.

Técnica de inyección

Las inyecciones subcutáneas suelen aplicarse en la grasa del abdomen o el muslo: limpia el sitio con una toallita de alcohol, pellizca la piel, inserta en el ángulo recomendado y rota los sitios para proteger el tejido. Consulta MedlinePlus para una guía paso a paso de inyección subcutánea.

Referencias generales de técnica aséptica e inyección para uso educativo — no son específicas de ningún compuesto de investigación.

ACTH 1-39 Preguntas

What is ACTH 1-39?
ACTH 1-39 (adrenocorticotropic hormone) is a naturally occurring 39-amino-acid peptide released by the pituitary gland. It is the full-length form of the hormone that signals the adrenal glands to produce cortisol.[6] It is also the active component in the clinically used drug Acthar (repository corticotropin injection).[5] In research, it is studied for both its hormonal effects and potential direct actions in the nervous system.
How does ACTH 1-39 work?
ACTH 1-39 binds to corticotropin (melanocortin) receptors on adrenal cells, triggering cortisol production.[2] These same receptors are also found on brain cells — neurons and glial cells — which is why researchers are investigating whether ACTH 1-39 has direct protective effects in the nervous system that are independent of cortisol.[4] The hypothalamus regulates the whole chain by releasing corticotropin-releasing hormone.[1]
What is ACTH 1-39 used for in research?
Scientists are studying ACTH 1-39 for neuroprotection, myelin biology, and HPA axis physiology. Lab studies show it can protect rat forebrain neurons from excitotoxic and inflammatory damage[4] and can prompt support cells (astroglia) to shield myelin-producing oligodendrocytes.[3] Researchers are also comparing its pharmacokinetics and cortisol-stimulating effects to shorter ACTH fragments and steroids.[5]
How is ACTH 1-39 dosed in research?
Dosing in research varies by model and study design. A Phase 1 clinical study used subcutaneous injection on a twice-weekly schedule.[5] There is no standardized research dose established for all contexts. See the dosage chart on this page and use the calculator for unit conversions. This is not medical dosing advice — ACTH 1-39 is for research use only.
How do you reconstitute ACTH 1-39?
Lyophilized ACTH 1-39 powder is typically dissolved in bacteriostatic water or sterile saline. Add solvent slowly and swirl gently — never shake. Once mixed, store the solution at 2–8 °C and use within the window specified by your supplier. Dry, unopened stock should be kept frozen at −20 °C or below, protected from light and moisture. Always record the reconstitution date on the vial.
Is ACTH 1-39 safe?
ACTH 1-39 is a research compound, not approved for general human use outside of regulated clinical or pharmaceutical contexts. Its clinical form (Acthar) has an established safety profile under medical supervision, but research-grade peptides carry additional unknowns. Lab studies suggest cellular protective effects at tested concentrations,[4][3] but pharmacokinetic differences between formulations are significant.[5] Always follow institutional safety protocols. Nothing here is medical advice.